by IR Team | Apr 11, 2022 | News
The challenge has been in early detection of inflammation. Matrix metalloproteinase-9 (MMP-9), an inflammatory biomarker consistently elevated in the tears of dry eye patients, may accelerate early diagnosis when detected. AXIM Biotechnologies, Inc. recently announced...
by IR Team | Apr 8, 2021 | News
Axim Biotechnologies has developed a rapid quantitative tear test to detect an inflammatory biomarker for dry eye disease, according to a press release. Diagnosis and treatment of dry eye disease (DED) can be difficult because of the discordance between signs and...
by IR Team | Mar 24, 2021 | News
AXIM Biotechnologies Inc. (AXIM.OB) said that its manufacturing partner, Empowered Diagnostics, has filed an Emergency Use Authorization or EUA application with the US Food and Drug Administration for the approval to use ImmunoPass, the company’s rapid test that...
by IR Team | Mar 17, 2021 | News
After a little over a year of expedited research, financial hardship and over 500K deaths in the US, we’re finally starting to see the light at the end of the COVID-19 tunnel. But while the widespread rollout of vaccines has been encouraging, there are many...
by IR Team | Mar 16, 2021 | News
Would an “immunity passport” be more effective? The vaccines are still in the early stages of being studied, but they’re thought to be highly effective. However, there are questions that remain. For example, it’s not clear if a vaccinated person who gets the virus can...
by IR Team | Mar 9, 2021 | News
The Company conducted two studies, one in partnership with the Company’s manufacturing partner Empowered Diagnostics and the second in partnership with a top accredited university medical center. The main goal of these studies was to identify the ability of operators...
